Canada's IM Cannabis Q2 loss widens as revenue drops, finance expenses rise - IMCC News | RalliesCanada's IM Cannabis Q2 loss widens as revenue drops, finance expenses rise
I
IMCC• Outlook
- Company did not provide specific guidance for future quarters or the full year
Key details
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|
| Q2 Revenue | | C$7.59 mln | |
| Q2 Loss Per Share | | C$0.47 | |
Result drivers
- Finance expenses - Finance expenses rose to C$2.9 mln from C$1.8 mln yr/yr, contributing to wider net loss
- Revenue decline - Revenue fell to C$7.6 mln from C$12.7 mln yr/yr
Quarterly results
- Canada-Israel medical cannabis platform's Q2 revenue fell sharply yr/yr, net loss widened
- Company reported shareholders' deficit and cash declined to C$1.6 mln as of June 30, 2026
- Gross profit and operating loss worsened compared to Q2 last year
